These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 7691188)

  • 21. Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy.
    Hershfield MS
    Semin Hematol; 1998 Oct; 35(4):291-8. PubMed ID: 9801258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble Babies to an Approved Drug.
    Ferrua F; Aiuti A
    Hum Gene Ther; 2017 Nov; 28(11):972-981. PubMed ID: 28847159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Flow cytometry analysis of adenosine deaminase (ADA) expression: a simple and reliable tool for the assessment of ADA-deficient patients before and after gene therapy.
    Otsu M; Hershfield MS; Tuschong LM; Muul LM; Onodera M; Ariga T; Sakiyama Y; Candotti F
    Hum Gene Ther; 2002 Feb; 13(3):425-32. PubMed ID: 11860709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene therapy for adenosine deaminase deficiency.
    Aiuti A; Ficara F; Cattaneo F; Bordignon C; Roncarolo MG
    Curr Opin Allergy Clin Immunol; 2003 Dec; 3(6):461-6. PubMed ID: 14612670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction.
    Gaspar HB; Cooray S; Gilmour KC; Parsley KL; Zhang F; Adams S; Bjorkegren E; Bayford J; Brown L; Davies EG; Veys P; Fairbanks L; Bordon V; Petropoulou T; Kinnon C; Thrasher AJ
    Sci Transl Med; 2011 Aug; 3(97):97ra80. PubMed ID: 21865538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bone marrow transplantation and alternatives for adenosine deaminase deficiency.
    Gaspar HB
    Immunol Allergy Clin North Am; 2010 May; 30(2):221-36. PubMed ID: 20493398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients.
    Bordignon C; Notarangelo LD; Nobili N; Ferrari G; Casorati G; Panina P; Mazzolari E; Maggioni D; Rossi C; Servida P; Ugazio AG; Mavilio F
    Science; 1995 Oct; 270(5235):470-5. PubMed ID: 7570000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Towards a rAAV-based gene therapy for ADA-SCID: from ADA deficiency to current and future treatment strategies.
    Silver JN; Flotte TR
    Pharmacogenomics; 2008 Jul; 9(7):947-68. PubMed ID: 18597656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates.
    Kohn DB; Hershfield MS; Carbonaro D; Shigeoka A; Brooks J; Smogorzewska EM; Barsky LW; Chan R; Burotto F; Annett G; Nolta JA; Crooks G; Kapoor N; Elder M; Wara D; Bowen T; Madsen E; Snyder FF; Bastian J; Muul L; Blaese RM; Weinberg K; Parkman R
    Nat Med; 1998 Jul; 4(7):775-80. PubMed ID: 9662367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The ADA human gene therapy clinical protocol.
    Hum Gene Ther; 1990; 1(3):327-62. PubMed ID: 2081198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Gene therapy for adenosine deaminase deficiency].
    Sakiyama Y; Ariga T; Ohtsu M
    Nihon Rinsho; 2005 Mar; 63(3):448-52. PubMed ID: 15773344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiency.
    Reinhardt B; Habib O; Shaw KL; Garabedian E; Carbonaro-Sarracino DA; Terrazas D; Fernandez BC; De Oliveira S; Moore TB; Ikeda AK; Engel BC; Podsakoff GM; Hollis RP; Fernandes A; Jackson C; Shupien S; Mishra S; Davila A; Mottahedeh J; Vitomirov A; Meng W; Rosenfeld AM; Roche AM; Hokama P; Reddy S; Everett J; Wang X; Luning Prak ET; Cornetta K; Hershfield MS; Sokolic R; De Ravin SS; Malech HL; Bushman FD; Candotti F; Kohn DB
    Blood; 2021 Oct; 138(15):1304-1316. PubMed ID: 33974038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo kinetics of transduced cells in peripheral T cell-directed gene therapy: role of CD8+ cells in improved immunological function in an adenosine deaminase (ADA)-SCID patient.
    Kawamura N; Ariga T; Ohtsu M; Kobayashi I; Yamada M; Tame A; Furuta H; Okano M; Egashira M; Niikawa N; Kobayashi K; Sakiyama Y
    J Immunol; 1999 Aug; 163(4):2256-61. PubMed ID: 10438969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The different extent of B and T cell immune reconstitution after hematopoietic stem cell transplantation and enzyme replacement therapies in SCID patients with adenosine deaminase deficiency.
    Serana F; Sottini A; Chiarini M; Zanotti C; Ghidini C; Lanfranchi A; Notarangelo LD; Caimi L; Imberti L
    J Immunol; 2010 Dec; 185(12):7713-22. PubMed ID: 21057082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene-transferred oligoclonal T cells predominantly persist in peripheral blood from an adenosine deaminase-deficient patient during gene therapy.
    Misaki Y; Ezaki I; Ariga T; Kawamura N; Sakiyama Y; Yamamoto K
    Mol Ther; 2001 Jan; 3(1):24-7. PubMed ID: 11162307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant adeno-associated virus-mediated gene transfer for the potential therapy of adenosine deaminase-deficient severe combined immune deficiency.
    Silver JN; Elder M; Conlon T; Cruz P; Wright AJ; Srivastava A; Flotte TR
    Hum Gene Ther; 2011 Aug; 22(8):935-49. PubMed ID: 21142972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term in vivo expression of a murine adenosine deaminase gene in rhesus monkey hematopoietic cells of multiple lineages after retroviral mediated gene transfer into CD34+ bone marrow cells.
    Bodine DM; Moritz T; Donahue RE; Luskey BD; Kessler SW; Martin DI; Orkin SH; Nienhuis AW; Williams DA
    Blood; 1993 Oct; 82(7):1975-80. PubMed ID: 7691243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term and real-world safety and efficacy of retroviral gene therapy for adenosine deaminase deficiency.
    Migliavacca M; Barzaghi F; Fossati C; Rancoita PMV; Gabaldo M; Dionisio F; Giannelli S; Salerio FA; Ferrua F; Tucci F; Calbi V; Gallo V; Recupero S; Consiglieri G; Pajno R; Sambuco M; Priolo A; Ferri C; Garella V; Monti I; Silvani P; Darin S; Casiraghi M; Corti A; Zancan S; Levi M; Cesana D; Carlucci F; Pituch-Noworolska A; AbdElaziz D; Baumann U; Finocchi A; Cancrini C; Ladogana S; Meinhardt A; Meyts I; Montin D; Notarangelo LD; Porta F; Pasquet M; Speckmann C; Stepensky P; Tommasini A; Rabusin M; Karakas Z; Galicchio M; Leonardi L; Duse M; Guner SN; Di Serio C; Ciceri F; Bernardo ME; Aiuti A; Cicalese MP
    Nat Med; 2024 Feb; 30(2):488-497. PubMed ID: 38355973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of patients with severe combined immunodeficiency due to adenosine deaminase (ADA) deficiency by autologous transplantation of genetically modified bone marrow cells.
    Hoogerbrugge PM; Vossen JM; v Beusechem VW; Valerio D
    Hum Gene Ther; 1992 Oct; 3(5):553-8. PubMed ID: 1420454
    [No Abstract]   [Full Text] [Related]  

  • 40. Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency.
    Cicalese MP; Ferrua F; Castagnaro L; Pajno R; Barzaghi F; Giannelli S; Dionisio F; Brigida I; Bonopane M; Casiraghi M; Tabucchi A; Carlucci F; Grunebaum E; Adeli M; Bredius RG; Puck JM; Stepensky P; Tezcan I; Rolfe K; De Boever E; Reinhardt RR; Appleby J; Ciceri F; Roncarolo MG; Aiuti A
    Blood; 2016 Jul; 128(1):45-54. PubMed ID: 27129325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.